References
- Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS statistical report. Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 2018; iv1–iv86
- Elsarrag M, Patel PD, Chatrath A, et al. Genomic and molecular characterization of pituitary adenoma pathogenesis: review and translational opportunities. Neurosurgical Focus. 2020;48(6):E11. DOI:https://doi.org/10.3171/2020.3.FOCUS20104.
- Russ S, Anastasopoulou C, Shafiq IPA 2022.
- Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020 Mar 5; 382(10):937–950. https://doi.org/10.1056/NEJMra1810772
- Melmed S. Pituitary medicine from discovery to patient-focused outcomes. J ClinEndocrinol Metab. 2016;101(3):769–777.https://doi.org/10.1210/jc.2015-3653
- Herman V, Drazin NZ, Gonsky R, et al. Molecular screening of pituitary adenomas for gene mutations and rearrangements. The Journal of Clinical Endocrinology and Metabolism. 1993;77(1):50–55. DOI:https://doi.org/10.1210/jcem.77.1.8100831.
- Mete O, Lopes MB. Overview of the 2017 WHO classification of pituitary tumors. Endocrine Pathology. 2017;28(3):228–243.
- Melmed S, Kaiser UB, Lopes MB, et al. Clinical biology of the pituitary adenoma. Endocr Rev. 2022 Apr 8;https://doi.org/10.1210/endrev/bnac010
- Daly AF, Beckers A. The epidemiology of pituitary adenomas. Endocrinology and Metabolism Clinics of North America. 2020;49(3):347–355.
- Salomon MP, Wang X, Marzese DM, et al. The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly. Cushing’s Disease and Endocrine-Inactive Subtypes 2018; 4126–4136
- Ling C, Pease M, Shi L, et al. A pilot genome-scale profiling of DNA methylation in sporadic pituitary macroadenomas: association with tumor invasion and histopathological subtype. PLoS One. 2014;9(4):e96178. DOI:https://doi.org/10.1371/journal.pone.0096178.
- Neou M, Villa C, Armignacco R, et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell. 2020 Jan 13 37(1):123–134 e5. DOI: https://doi.org/10.1016/j.ccell.2019.11.002.
- Ciccarelli A, Daly AF, Beckers A, et al. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3–6. DOI:https://doi.org/10.1007/s11102-005-5079-0.
- Raappana A, Koivukangas J, Ebeling T, et al. Incidence of pituitary adenomas in Northern Finland in 1992–2007. The Journal of Clinical Endocrinology and Metabolism. 2010;95(9):4268–4275. DOI:https://doi.org/10.1210/jc.2010-0537.
- Pekić S, Medic Stojanoska M, Popovic V, et al. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period. Challenges in Diagnosis and Management 2019; 28–33
- Liu X, Tang C, Wen G, et al. The mechanism and pathways of dopamine and dopamine agonists in prolactinomas. Frontiers of Endocrinology (Lausanne). 2018;9:768. DOI:https://doi.org/10.3389/fendo.2018.00768.
- Park JY, Choi W, Hong AR, et al. Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas. Pituitary. 2021 Dec;24(6):955–963. DOI:https://doi.org/10.1007/s11102-021-01168-x.
- Baussart B, Villa C, Jouinot A, et al. Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur J Endocrinol. 2021 Oct 21 185(6):783–791. https://doi.org/10.1530/EJE-21-0293
- Delgrange E, Trouillas J, Maiter D, et al. Sex-Related difference in the growth of prolactinomas: a clinical and proliferation marker study 1. The Journal of Clinical Endocrinology and Metabolism. 1997;82(7):2102–2107. DOI:https://doi.org/10.1210/jcem.82.7.4088.
- Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest. 2002 Jan;109(2):277–283.
- Heaney AP, Horwitz GA, Wang Z, et al. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med. 1999 Nov;5(11):1317–1321. DOI:https://doi.org/10.1038/15275.
- Wierinckx A, Delgrange E, Bertolino P, et al. Sex-related differences in lactotroph tumor aggressiveness are associated with a specific gene-expression signature and genome instability. Frontiers in Endocrinology. 2018;9. DOI:https://doi.org/10.3389/fendo.2018.00706.
- Bernard V, Villa C, Auguste A, et al. Natural and molecular history of prolactinoma: insights from a Prlr-/- mouse model. Oncotarget. 2018;9(5):6144–6155. DOI:https://doi.org/10.18632/oncotarget.23713.
- Gorvin CM, Newey PJ, Rogers A, et al. Association of prolactin receptor (PRLR) variants with prolactinomas. Human Molecular Genetics. 2019;28(6):1023–1037. DOI:https://doi.org/10.1093/hmg/ddy396.
- Xu RK, Wu XM, Di AK, et al. Pituitary prolactin-secreting tumor formation: recent developments. Biological Signals and Receptors. 2000;9(1):1–20. DOI:https://doi.org/10.1159/000014618.
- Bisson JR, Chan KJ, Safer JD. Prolactin levels do not rise among transgender women treated with estradiol and spironolactone. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2018;24(7):646–651.
- Cunha FS, Domenice S, Câmara VL, et al. Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia. 2015;47(6):680–684. DOI:https://doi.org/10.1111/and.12317.
- García-Malpartida K, Martín-Gorgojo A, Rocha M, et al. Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual. Fertility and Sterility. 2010;94(3):1097.e13–1097.e15. DOI:https://doi.org/10.1016/j.fertnstert.2010.01.076.
- Veldhuis JD. The estrogen-prolactinoma nexus in humans—;fact or fable? Mayo Clinic Proceedings. 1989;9:1190–1192. DOI:https://doi.org/10.1016/s0025-6196(12)64991-x
- Hulting A-L, Werner S, Hagenfeldt K. Oral contraceptive steroids do not promote the development or growth of prolactinomas. Contraception. 1983;27(1):69–73.
- Jones JR, Kemmann E, Norwood PK. Oral contraceptive exposure of amenorrheic women with and without prolactinomas. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 1981;19(5):381–387.
- Shy KK. Oral contraceptive use and the occurrence of pituitary prolactinoma. JAMA. 1983;249(16):2204.
- Wierinckx A, Roche M, Legras-Lachuer C, et al. MicroRNAs in pituitary tumors. Mol Cell Endocrinol. 2017 Nov 15;456:51–61. https://doi.org/10.1016/j.mce.2017.01.021.
- Roche M, Wierinckx A, Croze S, et al. Deregulation of miR-183 and KIAA0101 in aggressive and malignant pituitary tumors. Frontiers in Medicine. 2015;2. DOI:https://doi.org/10.3389/fmed.2015.00054.
- Chang C-N, Feng M-J, Chen Y-L, et al. p15PAF is an Rb/E2F-regulated S-phase protein essential for DNA synthesis and cell cycle progression. PloS one. 2013;8(4):e61196. DOI:https://doi.org/10.1371/journal.pone.0061196.
- Faltermeier CM, Magill ST, Blevins LS, et al. Molecular biology of pituitary adenomas. Neurosurgery Clinics of North America. 2019;30(4):391–400. DOI:https://doi.org/10.1016/j.nec.2019.05.001.
- Gadelha MR, Kasuki L, Lim DST, et al. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019 Feb 1 40(1):268–332. https://doi.org/10.1210/er.2018-00115
- Boguslawska A, Korbonits M. Genetics of acromegaly and gigantism. J Clin Med. 2021 Mar 29; 10(7):1377. https://doi.org/10.3390/jcm10071377
- Melmed S. Acromegaly pathogenesis and treatment. The Journal of Clinical Investigation. 2009;119(11):3189–3202.
- Fleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021 Feb;24(1):1–13. DOI:https://doi.org/10.1007/s11102-020-01091-7.
- Obi C, Achebe C. Nature reviews endocrinology: acromegaly. J Endocrinol and Disord. 2018: 1
- Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010 Nov;95(11):E373–83. DOI:https://doi.org/10.1210/jc.2009-2556.
- Srirangam Nadhamuni V, Korbonits M. Novel insights into pituitary tumorigenesis: genetic and epigenetic mechanisms. Endocr Rev. 2020 Dec 1;416. DOI:https://doi.org/10.1210/endrev/bnaa006.
- Barry S, Carlsen E, Marques P, et al. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene. 2019 Jul;38(27):5381–5395. DOI:https://doi.org/10.1038/s41388-019-0779-5.
- Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019 Feb;20(2):69–84.
- Brittain AL, Basu R, Qian Y, et al. Growth hormone and the epithelial-to-mesenchymal transition. J Clin Endocrinol Metab. 2017 Oct 1 102(10):3662–3673. https://doi.org/10.1210/jc.2017-01000
- Kamilaris CDC, Faucz FR, Voutetakis A, et al. Carney Complex. Exp Clin Endocrinol Diabetes. 2019 Feb;127(2–03):156–164. DOI:https://doi.org/10.1055/a-0753-4943.
- Abboud D, Daly AF, Dupuis N, et al. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11. Nat Commun. 2020 Sep 21 11(1):4752. https://doi.org/10.1038/s41467-020-18500-x
- Välimäki N, Demir H, Pitkänen E, et al. Whole-genome sequencing of Growth Hormone (GH)-secreting pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 2015;100(10):3918–3927. DOI:https://doi.org/10.1210/jc.2015-3129.
- Välimäki N, Schalin-Jäntti C, Karppinen A, et al. Genetic and epigenetic characterization of growth hormone-secreting pituitary tumors. Molecular Cancer Research : MCR. 2019;17(12):2432–2443. DOI:https://doi.org/10.1158/1541-7786.MCR-19-0434.
- Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014 Dec 18 371(25):2363–2374. https://doi.org/10.1056/NEJMoa1408028
- Bertherat J, Chanson P, Montminy M, et al. The cyclic adenosine 3’,5’-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Molecular Endocrinology (Baltimore, Md.). 1995;9(7):777–783. DOI:https://doi.org/10.1210/mend.9.7.7476961.
- Ben-Shlomo A, Deng N, Ding E, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J Clin Invest. 2020 Nov 2 130(11):5738–5755. https://doi.org/10.1172/JCI138540
- Bi WL, Horowitz P, Greenwald NF, et al. Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res. 2017 Apr 1 23(7):1841–1851. https://doi.org/10.1158/1078-0432.CCR-16-0790
- Song ZJ, Reitman ZJ, Ma ZY, et al. The genome-wide mutational landscape of pituitary adenomas. Cell Res. 2016 Nov;26(11):1255–1259. DOI:https://doi.org/10.1038/cr.2016.114.
- Binse I, Ueberberg B, Sandalcioglu IE, et al. Expression analysis of GADD45γ, MEG3, and p8 in pituitary adenomas. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 2014;46(9):644–650. DOI:https://doi.org/10.1055/s-0034-1383566.
- Mezzomo LC, Gonzales PH, Pesce FG, et al. Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas. Pituitary. 2012;15(3):420–427. DOI:https://doi.org/10.1007/s11102-011-0340-1.
- Zhang X, Sun H, Danila DC, et al. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. The Journal of Clinical Endocrinology and Metabolism. 2002;87(3):1262–1267. DOI:https://doi.org/10.1210/jcem.87.3.8315.
- Yang Z, Yik JHN, Chen R, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Molecular Cell. 2005;19(4):535–545. DOI:https://doi.org/10.1016/j.molcel.2005.06.029.
- Shi C, Ye Z, Han J, et al. BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma. Neuro Oncology. 2020;22(8):1114–1125. DOI:https://doi.org/10.1093/neuonc/noaa084.
- Madan A, Markison S, Betz SF, et al. Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022;25(2):328–339. DOI: https://doi.org/10.1007/s11102-021-01201-z
- Cossu G, Daniel RT, Pierzchala K, et al. Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management. Pituitary. 2019;22(1):79–88. DOI:https://doi.org/10.1007/s11102-018-0921-3.
- Moran C, Chatterjee K. Resistance to thyroid hormone due to defective thyroid receptor alpha. Best Practice & Research. Clinical Endocrinology & Metabolism. 2015;29(4):647–657.
- Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. The New England Journal of Medicine. 2001;344(7):501–509.
- Azzalin A, Appin CL, Schniederjan MJ, et al. Comprehensive evaluation of thyrotropinomas: single-center 20-year experience. Pituitary. 2016;19(2):183–193. DOI:https://doi.org/10.1007/s11102-015-0697-7.
- Yamada S, Fukuhara N, Horiguchi K, et al. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. Journal of Neurosurgery. 2014;121(6):1462–1473. DOI:https://doi.org/10.3171/2014.7.JNS1471.
- Dyer MW, Gnagey A, Jones BT, et al. Perianesthetic management of patients with thyroid-stimulating hormone-secreting pituitary adenomas. J Neurosurg Anesthesiol. 2017 Jul;29(3):341–346. DOI:https://doi.org/10.1097/ANA.0000000000000325.
- Kirkman MA, Jaunmuktane Z, Brandner S, et al. Active and silent thyroid-stimulating hormone-expressing pituitary adenomas: presenting symptoms, treatment, outcomes, and recurrence. World Neurosurgery. 2014;82(6):1224–1231. DOI:https://doi.org/10.1016/j.wneu.2014.03.031.
- van Varsseveld Nc, Bisschop PHLT, Biermasz PHLT, et al. A long-term follow-up study of eighteen patients with thyrotrophin-secreting pituitary adenomas. Clinical Endocrinology. 2014;80(3):395–402. DOI:https://doi.org/10.1111/cen.12290.
- Ando S, Sarlis NJ, Oldfield EH, et al. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. The Journal of Clinical Endocrinology and Metabolism. 2001;86(11):5572–5576. DOI:https://doi.org/10.1210/jcem.86.11.7984.
- Tagami T, Usui T, Shimatsu A, et al. Aberrant expression of thyroid hormone receptor beta isoform may cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma. The Journal of Clinical Endocrinology and Metabolism. 2011;96(6):E948–52. DOI:https://doi.org/10.1210/jc.2010-2496.
- Sapkota S, Horiguchi K, Tosaka M, et al. Whole-Exome Sequencing Study of Thyrotropin-Secreting Pituitary Adenomas. The Journal of Clinical Endocrinology and Metabolism. 2017;102(2):566–575. DOI:https://doi.org/10.1210/jc.2016-2261.
- Matsunaga H, Sasaki S, Suzuki S, et al. Essential role of GATA2 in the negative regulation of type 2 deiodinase gene by liganded thyroid hormone receptor β2 in thyrotroph. PloS one. 2015;10(11):e0142400. DOI:https://doi.org/10.1371/journal.pone.0142400.
- Amlashi FG, Tritos NA. Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management. Endocrine. 2016;52(3):427–440 . DOI:https://doi.org/10.1007/s12020-016-0863-3.
- Fliers E, van Furth Wr, Bisschop PH. Cure of a thyrotrophin (TSH)-secreting pituitary adenoma by medical therapy. Clinical Endocrinology. 2012;77(5):788–790.
- Kuhn JM, Arlot S, Lefebvre H, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. The Journal of Clinical Endocrinology and Metabolism. 2000;85(4):1487–1491. DOI:https://doi.org/10.1210/jcem.85.4.6548.
- Gatto F, Barbieri F, Castelletti L, et al. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary. 2011;14(2):141–147. DOI:https://doi.org/10.1007/s11102-010-0271-2.
- Horiguchi K, Yamada M, Umezawa R, et al. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocrine Journal. 2007;54(3):371–378. DOI:https://doi.org/10.1507/endocrj.k06-177.
- Yoshihara A, Isozaki O, Hizuka N, et al. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocrine Journal. 2007;54(1):133–138. DOI:https://doi.org/10.1507/endocrj.k06-133.
- Beck-Peccoz P, Giavoli C, Lania A, et al. A 2019 update on TSH-secreting pituitary adenomas . Journal of Endocrinological Investigation. 2019;42(12):1401–1406. DOI:https://doi.org/10.1007/s40618-019-01066-x.
- Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847–875. DOI:https://doi.org/10.1016/S2213-8587(21)00235-7.
- Alexandraki KI, Kaltsas GA, Isidori AM, et al. The prevalence and characteristic features of cyclicity and variability in Cushing’s disease. European Journal of Endocrinology. 2009;160(6):1011–1018. DOI:https://doi.org/10.1530/EJE-09-0046.
- Lonser RR, Nieman L, Oldfield EH. Cushing’s disease: pathobiology, diagnosis, and management. Journal of Neurosurgery. 2017;126(2):404–417.
- Mizuno E, Iura T, Mukai A, et al. Regulation of epidermal growth factor receptor down-regulation by ubpy-mediated deubiquitination at endosomes. Molecular Biology of the Cell. 2005;16(11):5163–5174. DOI:https://doi.org/10.1091/mbc.e05-06-0560.
- Huang C, Shi Y, Zhao Y. USP8 mutation in Cushing’s disease. Oncotarget. 2015;6(21):18240–18241.
- Reincke M, Sbiera S, Hayakawa A, et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nature Genetics. 2015;47(1):31–38. DOI:https://doi.org/10.1038/ng.3166.
- Chen J, Jian X, Deng S, et al. Identification of recurrent USP48 and BRAF mutations in Cushing’s disease. Nature Communications. 2018;9(1):3171. DOI:https://doi.org/10.1038/s41467-018-05275-5.
- Woodbury ME, Ikezu T. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology. 2014;9(2):92–101.
- Zheng W, Nowakowski RS, Vaccarino FM. Fibroblast growth factor 2 is required for maintaining the neural stem cell pool in the mouse brain subventricular zone. Developmental Neuroscience. 2004;26(2–4):181–196.
- Zhu X, Lee K, Asa SL, et al. Epigenetic Silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. The American Journal of Pathology. 2007;170(5):1618–1628. DOI:https://doi.org/10.2353/ajpath.2007.061111.
- Chang M, Yang C, Bao X, et al. Genetic and epigenetic causes of pituitary adenomas. Frontiers in Endocrinology. 2021;11. DOI:https://doi.org/10.3389/fendo.2020.596554.
- Araki T, Liu. Cell cycle regulators and lineage-specific therapeutic targets for cushing disease. Front Endocrinol (Lausanne). 2018;9:444. DOI:https://doi.org/10.3389/fendo.2018.00444. NA
- Liu NA, Araki T, Cuevas-Ramos D, et al. Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for cushing disease. J Clin Endocrinol Metab. 2015 Jul;100(7):2557–2564. DOI:https://doi.org/10.1210/jc.2015-1606.
- Pivonello R, Fleseriu M, Newell-Price J, et al. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. The Lancet. Diabetes & Endocrinology. 2020;8(9):748–761. DOI:https://doi.org/10.1016/S2213-8587(20)30240-0.
- Fleseriu M, Castinetti F. Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies. Pituitary. 2016;19(6):643–653.
- Creemers SG, Feelders RA, de Jong FH, et al. Levoketoconazole, the 2S,4R enantiomer of ketoconazole, a new steroidogenesis inhibitor for cushing’s syndrome treatment. 2021. p. e1618–e1630.
- Pivonello R, Elenkova A, Fleseriu M, et al. Levoketoconazole in the treatment of patients with cushing’s syndrome and diabetes mellitus: results from the sonics phase 3 study. Frontiers in Endocrinology. 2021;12. DOI:https://doi.org/10.3389/fendo.2021.595894.
- Lee M, Lupp A, Mendoza N, et al. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocrine-related Cancer. 2015;22(1):111–119. DOI:https://doi.org/10.1530/ERC-14-0472.
- Jameson JL, Klibanski A, Black PM, et al. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas. The Journal of Clinical Investigation. 1987;80(5):1472–1478. DOI:https://doi.org/10.1172/JCI113228.
- Ilie MD, Raverot G. Treatment options for gonadotroph tumors: current state and perspectives. The Journal of Clinical Endocrinology & Metabolism. 2020;105(10):e3507–e3518.
- Batista RL, Musolino NRC, Cescato VAS, et al. Cabergoline in the management of residual nonfunctioning pituitary adenoma: a single-center, open-label, 2-year randomized clinical trial. American Journal of Clinical Oncology. 2019;42(2):221–227. DOI:https://doi.org/10.1097/COC.0000000000000505.
- Fusco A, Giampietro A, Bianchi A, et al. Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case–control study. Pituitary. 2012;15(4):571–578. DOI:https://doi.org/10.1007/s11102-011-0370-8.
- Zawada NB, Kunert-Radek J, Pawlikowski M, et al. An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly. Endokrynologia Polska. 2015;67(3):292–8. DOI:https://doi.org/10.5603/EP.a2016.0043.
- Ilie MD, Vasiljevic A, Louvet C, et al. Gonadotroph Tumors Show Subtype Differences that Might Have Implications for Therapy. Cancers (Basel). 2020;12(4):1012. DOI:https://doi.org/10.3390/cancers12041012.
- Cote DJ, Smith TR, Sandler CN, et al. Functional gonadotroph adenomas: case series and report of literature. 2016. p. 823–831.
- Falch CM, Sundaram AYM, Oystese KA, et al. Gene expression profiling of fast- and slow-growing non-functioning gonadotroph pituitary adenomas. Eur J Endocrinol. 2018 Mar;178(3):295–307. DOI:https://doi.org/10.1530/EJE-17-0702.
- Wang X, Li X, Wang Z. lncRNA MEG3 inhibits pituitary tumor development by participating in cell proliferation, apoptosis and EMT processes. Oncol Rep. 2021 Apr;45(4). DOI:https://doi.org/10.3892/or.2021.7991.
- Zhu D, Xiao Z, Wang Z, et al. MEG3/MIR-376B-3P/HMGA2 axis is involved in pituitary tumor invasiveness. Journal of Neurosurgery. 2020;1–13. DOI:https://doi.org/10.3171/2019.10.JNS191959.
- Chesnokova V, Zonis S, Zhou C, et al. Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PloS one. 2011;6(3):e17924. DOI:https://doi.org/10.1371/journal.pone.0017924.
- Lee M, Marinoni I, Irmler M, et al. Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas. Acta Neuropathologica. 2013;126(1):137–150. doi:https://doi.org/10.1007/s00401-013-1132-7.
- Cui Y, Li C, Jiang Z, et al. Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors. Neuro-oncology. 2021;23(11):1859–1871. DOI:https://doi.org/10.1093/neuonc/noab102.
- Taniguchi-Ponciano K, Andonegui-Elguera S, Peña-Martínez, E, et al. Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors. Scientific Reports. 2020;10(1):19373. DOI:https://doi.org/10.1038/s41598-020-76555-8.
- Inoshita N, Nishioka H. The 2017 WHO classification of pituitary adenoma: overview and comments. Brain Tumor Pathology. 2018;35(2):51–56.
- Haddad AF, Young JS, Oh T, et al. Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. Neurosurgical Focus. 2020;48(6):E13. DOI:https://doi.org/10.3171/2020.3.FOCUS20114.
- Almeida JP, Stephens CC, Eschbacher JM, et al. Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary. 2019;22(5):514–519. DOI:https://doi.org/10.1007/s11102-019-00981-9.
- Hong SW, Kim SH, Lim SH, et al. Clinical relevance of New World Health Organization classification system for pituitary adenomas: a validation study with 2-year experience. Frontiers in Oncology. 2021;11:739290.
- Sanchez-Tejada L, Sanchez-Ortiga R, Lamas C, et al. Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas. PloS one. 2017;12(7):e0180039. DOI:https://doi.org/10.1371/journal.pone.0180039.
- Nishioka H, Inoshita N, Mete O, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocrine Pathology. 2015;26(4):349–355. DOI:https://doi.org/10.1007/s12022-015-9398-z.
- Feng J, Sheng-Yuan Y, Chu-Zhong L, et al. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas. Molecular and cellular endocrinology. 2016;436:195–203. DOI:https://doi.org/10.1016/j.mce.2016.07.025.
- Yu G, Li C, Xie W, et al. Long non-coding RNA C5orf66-AS1 is downregulated in pituitary null cell adenomas and is associated with their invasiveness. Oncology Reports. 2017;38(2):1140–1148. DOI:https://doi.org/10.3892/or.2017.5739.
- Newey PJ, Nesbit MA, Rimmer AJ, et al. Whole-exome sequencing studies of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 2013 Apr;98(4):E796–800. DOI:https://doi.org/10.1210/jc.2012-4028.
- Turchini J, Sioson L, Clarkson A, et al. Utility of GATA-3 expression in the analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors. Endocr Pathol. 2020 Jun;31(2):150–155. DOI:https://doi.org/10.1007/s12022-020-09615-4.
- Marques P, Grossman AB, Korbonits M. The tumour microenvironment of pituitary neuroendocrine tumours. Front Neuroendocrinol. 2020 Jul;58:100852.
- Marques P, Silva AL, Lopez-Presa D, et al. The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications. Pituitary. 2022 Feb 22;https://doi.org/10.1007/s11102-022-01211-5
- Yagnik G, Rutowski MJ, Shah SS, et al. Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. Oncotarget. 2019 Mar 15 10(22):2212–2223. https://doi.org/10.18632/oncotarget.26775
- Iacovazzo D, Chiloiro S, Carlsen E, et al. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine. 2020 Mar;67(3):651–658. DOI:https://doi.org/10.1007/s12020-019-02145-y.
- Lu JQ, Adam B, Jack AS, et al. Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more t cells in growth hormone adenomas. Endocr Pathol. 2015 Sep;26(3):263–272. DOI:https://doi.org/10.1007/s12022-015-9383-6.
- Marques P, Barry S, Carlsen E, et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun. 2019 Nov 8 7(1):172. https://doi.org/10.1186/s40478-019-0830-3
- Yeung JT, Taylor HM, Young IM, et al. Unexpected hubness: a proof-of-concept study of the human connectome using pagerank centrality and implications for intracerebral neurosurgery. J Neurooncol. 2021 Jan;151(2):249–256. DOI:https://doi.org/10.1007/s11060-020-03659-6.
- Balkwill FR. The chemokine system and cancer. J Pathol. 2012 Jan;226(2):148–157.
- Grizzi F, Borroni EM, Vacchini A, et al. Pituitary adenoma and the chemokine network: a systemic view. Front Endocrinol (Lausanne). 2015;6:141.
- Mantovani A, Savino B, Locati M, et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010 Feb;21(1):27–39. DOI:https://doi.org/10.1016/j.cytogfr.2009.11.007.
- Marques P, Barry S, Carlsen E, et al. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. Endocr Relat Cancer. 2019 Dec;26(12):853–865. DOI:https://doi.org/10.1530/ERC-19-0327.
- Mei Y, Bi WL, Agolia J, et al. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary. 2021 Jun;24(3):359–373. DOI:https://doi.org/10.1007/s11102-020-01114-3.
- Xi Z, Jones PS, Mikamoto M, et al. The upregulation of molecules related to tumor immune escape in human pituitary adenomas. Front Endocrinol (Lausanne). 2021;12:726448.
- Zhou W, Zhang C, Zhang D, et al. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas. J Neurooncol. 2020 Sep;149(3):473–487. DOI:https://doi.org/10.1007/s11060-020-03636-z.
- Lin AL, Jonsson P, Tabar V, et al. Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab. 2018 Oct 1 103(10):3925–3930. https://doi.org/10.1210/jc.2018-01347
- Caccese M, Barbot M, Ceccato F, et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anticancer Drugs. 2020 Feb;31(2):199–204. DOI:https://doi.org/10.1097/CAD.0000000000000856.
- Kemeny HR, Elsamadicy AA, Farber SH, et al. Targeting PD-L1 initiates effective antitumor immunity in a murine model of cushing disease. Clin Cancer Res. 2020 Mar 1 26(5):1141–1151. https://doi.org/10.1158/1078-0432.CCR-18-3486
- Mei Y, Bi WL, Greenwald NF, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016 Nov 22 7(47):76565–76576. https://doi.org/10.18632/oncotarget.12088